Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.
With an increasingly aged population, many patients will present with diffuse large B-cell lymphoma in their 70s and 80s. Recently, several randomized studies have confirmed the benefit of rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and showed a substantial improvement in the outcome of fit elderly patients. This article reviews the efficacy and toxicity of the current treatment regimens applied for the treatment of diffuse large B-cell lymphoma in elderly patients and provides practical recommendations for the management of these patients.
Lugtenburg
Pieternella J
PJ
Department of Hematology, Erasmus MC, University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands. p.lugtenburg@erasmusmc.nl
Sonneveld
Pieter
P
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015897:Comorbidity; D005260:Female; D005853:Geriatrics / Q000379:methods; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000628:therapy*; D008297:Male; D008495:Medical Oncology / Q000379:methods; D010166:Palliative Care; D011379:Prognosis; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab